KALA BIO (NASDAQ:KALA) fell 11.86% on June 23, 2026, as post-split profit taking pressured the ocular biotech, with shares closing at $3.12.

Key Highlights

  • Fell 11.86%: KALA BIO closed at $3.12 on June 23 after moving $0.42 per share.
  • Catalyst: During the session, post-split profit taking pressured the ocular biotech.
  • Company: KALA BIO develops ocular medicines using a bioadhesive nanoparticle drug delivery platform.
  • Session: The stock finished at $3.12, while the available company record showed a disclosed catalyst for the move.

KALA BIO (NASDAQ:KALA) fell 11.86% on June 23, 2026, closing at $3.12 after a $0.42 per-share move. The session’s decline came as post-split profit taking pressured the ocular biotech, based on the available company disclosures and trading context.

The company filed no adverse update during the session. The decline appeared to be profit-taking following a strong recent run-up and the mechanical price distortion associated with KALA BIO's recent 1-for-50 reverse stock split.

KALA BIO develops ocular medicines using a bioadhesive nanoparticle drug delivery platform.

The company is focused on ocular drug delivery with its AMPPLIFY bioadhesive nanoparticle technology platform. The split-adjusted share count and post-reverse-split normalization dynamics can create elevated near-term volatility.

A reverse stock split reduces the number of shares outstanding and raises the quoted price per share in the same proportion. The corporate action does not by itself create an equivalent increase in the company’s total equity value, although the smaller float can increase near-term volatility.

The reported 11.86% move must therefore be read alongside the split mechanics. The session ended at $3.12, and no separate operating announcement accompanied the price adjustment.

For the June 23 close, the defining facts were the 11.86% decline, the $3.12 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.